Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AGORA-1 /ALFA 2100 Study : A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD and/or FLT3-TKD Relapse/Refractory (R/R) AML

NCT05199051 is registered in ClinicalTrials.gov with Centre Antoine Lacassagne as lead sponsor.

NCT NCT05199051
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05199051 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AGORA-1 /ALFA 2100 Study : A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD and/or FLT3-TKD Relapse/Refractory (R/R) AML
Lead sponsor
Centre Antoine Lacassagne
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 3, 2023
Completion date
July 10, 2028
Enrollment
19 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

aml, leukaemia (acute myeloid)